A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer

NCT05318573 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Urothelial Carcinoma
Advanced Non Small Cell Lung Cancer

Interventions

DRUG: Pembrolizumab
DRUG: FF-10832

Sponsor

Fujifilm Pharmaceuticals U.S.A., Inc.

Collaborators

[object Object]